In a mouse breast tumor model, Li et al. conjugated Salinomycin (SLM)-loaded PLGA NPs with an antibody against erbB-2 tyrosine-protein kinase receptor (HER2) for targeting HER2-positive CSCs [35]. This evidence concerns the gene ERBB2 and breast neoplasm.